drugset / Trial / NCT07224373
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
Timeline
- Start
- 2025-12-09
- Primary completion
- 2028-12-07
- Completion
- 2028-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | — | — |